4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-amine

Catalog No. :
ACSDEY912
CAS No. :
1218790-22-7
Molecular Formula :
C16H20BNO2
Molecular Weight :
269.15

IUPAC Name:4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-amine

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-amine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$153.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-amine
IUPAC Name4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-amine
MDL No.MFCD15143602
Molecular FormulaC16H20BNO2
Molecular Weight269.15
SMILESNC1=C2C=CC=CC2=C(B3OC(C)(C)C(C)(C)O3)C=C1
InChI KeyYAQGFMZVTUQUSY-UHFFFAOYSA-N
Synonym4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-amine;4-Aminonaphthalene-1-boronic acid, pinacol ester;4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-Naphthalenamine;1-Naphthalenamine, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.1218790-22-7
PubChem CID53217195

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H332-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACSDEY912 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. ACSLKN407 route compound structure diagram
    ACSLKN4072298-07-9 In Stock
  4. Then
  5. ACSDEY912 route product structure diagram
    ACSDEY9121218790-22-7 In Stock
Inquiry

2. ACSDEY912 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACVAFC569 route compound structure diagram
    ACVAFC5691565857-69-3 In Stock
  2. Then
  3. ACSDEY912 route product structure diagram
    ACSDEY9121218790-22-7 In Stock
Inquiry

Comments (0)